Related Experiment Videos
Arsenic trioxide and olanzapine co-administration: case analysis
Kenneth R Kaufman1, Saurabh Chhabra, Michael Levitt
1Department of Psychiatry, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA. kaufmakr@umdnj.edu
Abstract:
QTc prolongation is associated with arsenic trioxide (ATO) treatment of acute promyelocytic leukemia (APL). Olanzapine was safely co-administered with ATO to treat co-morbid psychiatric diagnoses. It is important to closely monitor for drug-drug interactions and cumulative drug adverse effects in patients receiving oncology agents and psychotropics. Further research is indicated to determine risk/benefit profiles of psychotropics co-administered with ATO. In light of current limited data, co-administration of psychotropics with ATO should be reported presenting both instances wherein no interactions are noted and those with adverse effects.
Related Concept Videos
Psychosis: Goals of Pharmacotherapy
Pharmaceutical Poisoning: Treatment Strategies
Pharmaceutical Poisoning: Potential Scenarios
Antipsychotic Drugs: Typical and Atypical Agents
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Psychosis and Antipsychotic Drugs: Overview